Literature DB >> 31202494

The incidence and risk factor of deep venous thrombosis after arthroscopically assisted anterior cruciate ligament reconstruction.

Hiroyuki Oshiba1, Masashi Nawata2, Susumu Morioka2, Takashige Momose2, Takashi Maeda2, Yukio Nakatsuchi2.   

Abstract

PURPOSE: To retrospectively analyze the incidence and risk factors of deep venous thrombosis (DVT) detected by ultrasonography after arthroscopically assisted Anterior Cruciate Ligament Reconstruction (ACLR).
METHODS: We retrospectively reviewed medical records of arthroscopically assisted ACLR surgery performed at our institution between 2012 and 2015. Revision ACLR, bone patella tendon bone (BTB) graft reconstruction, and concomitant multiple ligament reconstructions were excluded. We performed a standardized double-bundle reconstruction procedure using hamstrings graft for ACLR. All patients routinely received DVT screening by using venous ultrasonography on postoperative day 7 from 2012 to 2013, and postoperative days 7 and 14 from 2014 to 2015. The prevalence of DVT was calculated and clinical factors such as age, gender, Body Mass Index (BMI), operative time, and duration of tourniquet application were evaluated in relation to the risk factor of DVT.
RESULTS: Two hundred and fifty-six patients (129 men and 127 women) with a mean age of 28.9 were enrolled. Sixteen patients (6.6%) were detected with DVT on postoperative day 7. Among 146 patients who received venous ultrasonography on both postoperative days 7 and 14, DVT were detected in five additional patients on postoperative day 14. In a total of 21 patients who were diagnosed with DVT, two were proximal, the remaining 19 were distal, and no patient had progressed to pulmonary embolism (PE). In terms of predisposing factors for developing DVT on postoperative day 7, only age ≥30 showed a statistically significant higher risk of DVT (P = 0.03).
CONCLUSION: Incidence of DVT after ACLR detected by ultrasonography on postoperative day 7 was 6.6%. Patients aged ≥30 years have a potentially higher risk for developing DVT. Great care for DVT should be taken if prolonged immobilization is applied after ACLR surgery. LEVEL OF EVIDENCE: Level Ⅳ.
Copyright © 2019 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31202494     DOI: 10.1016/j.jos.2019.05.014

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  5 in total

1.  Anterior cruciate ligament tear increases the risk of venous thromboembolism: a population-based cohort study.

Authors:  Yilin Xiong; Xiaoxiao Li; Guanghua Lei; Chao Zeng; Jie Wei; Xiang Ding; Hui Li
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-08-19       Impact factor: 4.114

2.  Incidence and risk factors for symptomatic venous thromboembolism following anterior cruciate ligament reconstruction.

Authors:  Enrico M Forlenza; Kevin C Parvaresh; Matthew R Cohn; Ophelie Lavoie-Gagne; Zain M Khazi; Yining Lu; William Cregar; Brian Forsythe
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-05-10       Impact factor: 4.342

3.  Not Using a Tourniquet May Reduce the Incidence of Asymptomatic Deep Venous Thrombosis After ACL Reconstruction: An Observational Study.

Authors:  Masaki Nagashima; Kenichiro Takeshima; Nobuto Origuchi; Ryo Sasaki; Yoshifumi Okada; Toshiro Otani; Ken Ishii
Journal:  Orthop J Sports Med       Date:  2021-12-06

4.  Does anterior cruciate ligament reconstruction increase venous thromboembolism risk compared with knee meniscectomy under arthroscopy?

Authors:  Long Pang; Pengcheng Li; Hui Li; Xin Tang; Jing Zhu
Journal:  BMC Musculoskelet Disord       Date:  2022-03-18       Impact factor: 2.362

5.  Clinical Study of Neuromuscular Electrical Stimulation in the Prevention of Deep Venous Thrombosis of Lower Extremities after Anterior Cruciate Ligament Reconstruction.

Authors:  Jun Xiong; Qingsong Zhang; Yanan Li
Journal:  J Healthc Eng       Date:  2022-03-11       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.